LAB.MC Labiana Health S.A.

Healthcare Pharmaceuticals Madrid Exchange
5.15 EUR
Close of Oct 31, 2026
4.20 8.20
Market cap
EUR 43.7M
P/E
14.7x
P/B
8.68x
ROE
50.5%
Dividend yield
-
Fundamental score
1.6/5

Ratios use the latest price and the fiscal year ending Dec 2025.

Is LAB.MC undervalued?

Graham number
Price5.15
Graham value2.16
Premium138.3%

LAB.MC trades 138.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Labiana Health S.A. fundamental analysis

8 of 22 checks passed

ROE 2/2

High return on equity (50.5%), above 20%.

ROA 1/1

Return on assets (4.5%) is above the industry median (3.9%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (921.5%) is above the industry median (78.1%).

Revenue Growth 1/2

Revenue grew 9.1% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

High debt to equity (586.4%), above 100%.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 0/1

EBIT is 1.2x against interest expense, below 5x.

PE vs Market 1/1

PE (14.7x) is below the market median (16.3x).

PE vs Industry 1/1

PE (14.7x) is below the industry median (17.6x).

PBV 0/1

Price to book (8.7x) is above the industry median (1.7x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 127.8, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Labiana Health S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Labiana Health S.A.

Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, North America, and internationally. It offers anesthetics-sedatives, anti-infectives, anti-inflammatories, antiparasitics, hormonals, nutritional products, metabolism regulators, and vitamin products. The company also provides sterile and lyophilized dosage forms, and bacterial vaccines; and Fosfomycin trometamol under the Fosfomicina La…

Full company profile